Company Profile
CanSino Biologics develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease. Its portfolio also includes Ad5-EBOV, an Ebola virus vaccine, and MCV2 and MCV4 vaccines for the prevention of N. meningitides.
It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Additionally, it develops Tdcp Adolescent and Adult vaccine for treating pertussis.
Its portfolio also includes PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial, PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial, and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. It also is developing various preclinical stage products, including DTcP-Hib Combo vaccine.
Its portfolio also includes CS-2023 to treat meningitis, CS-2028 for treating multivalent conjugate vaccine, CS-2032 for hingles, CS-2036 to treat polio, CS-2047 for treating tetanus, and CS-2201 DTcP for combination vaccine. Incorporated in 2009, the company is headquartered in Tianjin, the People's Republic of China.